Novo Nordisk reported on November 25, 2025, that its phase 2 trial of amycretin for type 2 diabetes showed significant weight loss of up to 14.5% and HbA1c reductions with 89.1% of participants achieving levels below 7%. This trial marks an important advancement in diabetes treatment, supporting the company's upcoming phase 3 development plan.